Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing novel medicines for the treatment of fibrotic diseases across various organs
Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing novel medicines for the treatment of fibrotic diseases across various organs. The company's main offerings include anti-fibrotic protein therapeutics that target and inhibit cellular communication network (CCN) signaling pathways, which are central to the progression of fibrosis, aiming to prevent organ scarring and failure.